(CME) CME - Overview
Sector: Financial ServicesIndustry: Financial Data & Stock Exchanges | Exchange NASDAQ (USA) | Currency USD | Market Cap: 105.671m | Total Return 16.5% in 12m
Stock: Derivatives, Clearing, Data, Trading
Total Rating 47
Risk 22
Buy Signal -0.81
| Risk 5d forecast | |
|---|---|
| Volatility | 18.2% |
| Relative Tail Risk | 3.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 12.98 |
| Character TTM | |
|---|---|
| Beta | -0.131 |
| Beta Downside | -0.260 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.65% |
| CAGR/Max DD | 1.77 |
EPS (Earnings per Share)
Revenue
Description: CME CME March 05, 2026
CME Group Inc. operates global contract markets for futures and options trading. Its offerings span interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals. The company is a key player in the financial exchanges sector, which is characterized by high barriers to entry due to regulatory requirements and network effects.
CME provides essential clearinghouse services, including clearing, settling, and guaranteeing futures, options, and cleared swaps. This business model relies on transaction fees generated from trading activity. Additionally, it offers market data services, providing real-time and historical data to a diverse client base.
The company serves professional traders, financial institutions, investors, corporations, and governments. Consider exploring ValueRay for further in-depth analysis of CMEs market position and financial performance.
Headlines to watch out for
- Interest rate volatility drives derivatives trading volume
- Commodity price fluctuations impact futures contract demand
- Regulatory changes influence clearing house profitability
- Global economic uncertainty affects trading activity
- Technology investments enhance market data services revenue
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 4.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.50 > 1.0 |
| NWC/Revenue: 78.70% < 20% (prev 11.74%; Δ 66.96% < -1%) |
| CFO/TA 0.02 > 3% & CFO 4.28b > Net Income 4.04b |
| Net Debt (-666.2m) to EBITDA (5.72b): -0.12 < 3 |
| Current Ratio: 92.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.2m) vs 12m ago 0.05% < -2% |
| Gross Margin: 86.09% > 18% (prev 0.86%; Δ 8.52k% > 0.5%) |
| Asset Turnover: 3.88% > 50% (prev 4.46%; Δ -0.58% > 0%) |
| Interest Coverage Ratio: 31.40 > 6 (EBITDA TTM 5.72b / Interest Expense TTM 173.4m) |
Altman Z'' 0.53
| A: 0.03 (Total Current Assets 5.19b - Total Current Liabilities 55.8m) / Total Assets 198.55b |
| B: 0.03 (Retained Earnings 6.43b / Total Assets 198.55b) |
| C: 0.03 (EBIT TTM 5.45b / Avg Total Assets 168.00b) |
| D: 0.04 (Book Value of Equity 6.52b / Total Liabilities 169.82b) |
| Altman-Z'' Score: 0.53 = B |
Beneish M -1.21
| DSRI: 1.05 (Receivables 639.2m/573.1m, Revenue 6.52b/6.13b) |
| GMI: 1.00 (GM 86.09% / 86.13%) |
| AQI: 3.92 (AQ_t 0.97 / AQ_t-1 0.25) |
| SGI: 1.06 (Revenue 6.52b / 6.13b) |
| TATA: -0.00 (NI 4.04b - CFO 4.28b) / TA 198.55b) |
| Beneish M-Score: -1.21 (Cap -4..+1) = D |
What is the price of CME shares?
As of March 29, 2026, the stock is trading at USD 293.78 with a total of 1,538,868 shares traded.
Over the past week, the price has changed by -4.41%, over one month by -5.85%, over three months by +8.04% and over the past year by +16.49%.
Over the past week, the price has changed by -4.41%, over one month by -5.85%, over three months by +8.04% and over the past year by +16.49%.
Is CME a buy, sell or hold?
CME has received a consensus analysts rating of 3.39.
Therefor, it is recommend to hold CME.
- StrongBuy: 4
- Buy: 3
- Hold: 7
- Sell: 4
- StrongSell: 0
What are the forecasts/targets for the CME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 306.9 | 4.5% |
| Analysts Target Price | 306.9 | 4.5% |
CME Fundamental Data Overview March 27, 2026
P/E Trailing = 26.3142
P/E Forward = 25.974
P/S = 16.2402
P/B = 3.8364
P/EG = 5.8402
Revenue TTM = 6.52b USD
EBIT TTM = 5.45b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 55.8m USD (from shortTermDebt, last quarter)
Debt = 3.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -666.2m USD (from netDebt column, last quarter)
Enterprise Value = 104.88b USD (105.67b + Debt 3.76b - CCE 4.55b)
Interest Coverage Ratio = 31.40 (Ebit TTM 5.45b / Interest Expense TTM 173.4m)
EV/FCF = 25.01x (Enterprise Value 104.88b / FCF TTM 4.19b)
FCF Yield = 4.00% (FCF TTM 4.19b / Enterprise Value 104.88b)
FCF Margin = 64.31% (FCF TTM 4.19b / Revenue TTM 6.52b)
Net Margin = 62.02% (Net Income TTM 4.04b / Revenue TTM 6.52b)
Gross Margin = 86.09% ((Revenue TTM 6.52b - Cost of Revenue TTM 907.0m) / Revenue TTM)
Gross Margin QoQ = 85.38% (prev 84.55%)
Tobins Q-Ratio = 0.53 (Enterprise Value 104.88b / Total Assets 198.55b)
Interest Expense / Debt = 1.16% (Interest Expense 43.7m / Debt 3.76b)
Taxrate = 26.00% (410.4m / 1.58b)
NOPAT = 4.03b (EBIT 5.45b * (1 - 26.00%))
Current Ratio = 92.97 (Total Current Assets 5.19b / Total Current Liabilities 55.8m)
Debt / Equity = 0.13 (Debt 3.76b / totalStockholderEquity, last quarter 28.73b)
Debt / EBITDA = -0.12 (Net Debt -666.2m / EBITDA 5.72b)
Debt / FCF = -0.16 (Net Debt -666.2m / FCF TTM 4.19b)
Total Stockholder Equity = 27.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 4.04b / Total Assets 198.55b)
RoE = 14.48% (Net Income TTM 4.04b / Total Stockholder Equity 27.92b)
RoCE = 17.37% (EBIT 5.45b / Capital Employed (Equity 27.92b + L.T.Debt 3.42b))
RoIC = 12.86% (NOPAT 4.03b / Invested Capital 31.34b)
WACC = 5.36% (E(105.67b)/V(109.43b) * Re(5.52%) + D(3.76b)/V(109.43b) * Rd(1.16%) * (1-Tc(0.26)))
Discount Rate = 5.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.08%
[DCF] Terminal Value 87.39% ; FCFF base≈3.95b ; Y1≈4.43b ; Y5≈5.88b
[DCF] Fair Price = 483.6 (EV 172.75b - Net Debt -666.2m = Equity 173.42b / Shares 358.6m; r=6.0% [WACC]; 5y FCF grow 13.81% → 3.0% )
EPS Correlation: 89.72 | EPS CAGR: 7.53% | SUE: 1.83 | # QB: 2
Revenue Correlation: 88.90 | Revenue CAGR: 5.55% | SUE: -0.31 | # QB: 0
EPS next Quarter (2026-06-30): EPS=3.03 | Chg7d=+0.005 | Chg30d=+0.018 | Revisions Net=+2 | Analysts=12
EPS current Year (2026-12-31): EPS=12.09 | Chg7d=+0.050 | Chg30d=+0.170 | Revisions Net=+4 | Growth EPS=+8.0% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=12.71 | Chg7d=+0.002 | Chg30d=+0.059 | Revisions Net=+2 | Growth EPS=+5.1% | Growth Revenue=+4.0%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.1% (Discount Rate 7.9% - Earnings Yield 3.8%)
[Growth] Growth Spread = -1.5% (Analyst 2.6% - Implied 4.1%)
P/E Forward = 25.974
P/S = 16.2402
P/B = 3.8364
P/EG = 5.8402
Revenue TTM = 6.52b USD
EBIT TTM = 5.45b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 55.8m USD (from shortTermDebt, last quarter)
Debt = 3.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -666.2m USD (from netDebt column, last quarter)
Enterprise Value = 104.88b USD (105.67b + Debt 3.76b - CCE 4.55b)
Interest Coverage Ratio = 31.40 (Ebit TTM 5.45b / Interest Expense TTM 173.4m)
EV/FCF = 25.01x (Enterprise Value 104.88b / FCF TTM 4.19b)
FCF Yield = 4.00% (FCF TTM 4.19b / Enterprise Value 104.88b)
FCF Margin = 64.31% (FCF TTM 4.19b / Revenue TTM 6.52b)
Net Margin = 62.02% (Net Income TTM 4.04b / Revenue TTM 6.52b)
Gross Margin = 86.09% ((Revenue TTM 6.52b - Cost of Revenue TTM 907.0m) / Revenue TTM)
Gross Margin QoQ = 85.38% (prev 84.55%)
Tobins Q-Ratio = 0.53 (Enterprise Value 104.88b / Total Assets 198.55b)
Interest Expense / Debt = 1.16% (Interest Expense 43.7m / Debt 3.76b)
Taxrate = 26.00% (410.4m / 1.58b)
NOPAT = 4.03b (EBIT 5.45b * (1 - 26.00%))
Current Ratio = 92.97 (Total Current Assets 5.19b / Total Current Liabilities 55.8m)
Debt / Equity = 0.13 (Debt 3.76b / totalStockholderEquity, last quarter 28.73b)
Debt / EBITDA = -0.12 (Net Debt -666.2m / EBITDA 5.72b)
Debt / FCF = -0.16 (Net Debt -666.2m / FCF TTM 4.19b)
Total Stockholder Equity = 27.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.41% (Net Income 4.04b / Total Assets 198.55b)
RoE = 14.48% (Net Income TTM 4.04b / Total Stockholder Equity 27.92b)
RoCE = 17.37% (EBIT 5.45b / Capital Employed (Equity 27.92b + L.T.Debt 3.42b))
RoIC = 12.86% (NOPAT 4.03b / Invested Capital 31.34b)
WACC = 5.36% (E(105.67b)/V(109.43b) * Re(5.52%) + D(3.76b)/V(109.43b) * Rd(1.16%) * (1-Tc(0.26)))
Discount Rate = 5.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.08%
[DCF] Terminal Value 87.39% ; FCFF base≈3.95b ; Y1≈4.43b ; Y5≈5.88b
[DCF] Fair Price = 483.6 (EV 172.75b - Net Debt -666.2m = Equity 173.42b / Shares 358.6m; r=6.0% [WACC]; 5y FCF grow 13.81% → 3.0% )
EPS Correlation: 89.72 | EPS CAGR: 7.53% | SUE: 1.83 | # QB: 2
Revenue Correlation: 88.90 | Revenue CAGR: 5.55% | SUE: -0.31 | # QB: 0
EPS next Quarter (2026-06-30): EPS=3.03 | Chg7d=+0.005 | Chg30d=+0.018 | Revisions Net=+2 | Analysts=12
EPS current Year (2026-12-31): EPS=12.09 | Chg7d=+0.050 | Chg30d=+0.170 | Revisions Net=+4 | Growth EPS=+8.0% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=12.71 | Chg7d=+0.002 | Chg30d=+0.059 | Revisions Net=+2 | Growth EPS=+5.1% | Growth Revenue=+4.0%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.1% (Discount Rate 7.9% - Earnings Yield 3.8%)
[Growth] Growth Spread = -1.5% (Analyst 2.6% - Implied 4.1%)